Appetite suppressant compounds

Abstract

PYY-derived compounds that are altered from the naturally occurring peptide sequence, e.g., containing residues substituted at their gamma-carboxylic acid, epsilon-amino, or alpha-amino groups with fatty diacid groups, either directly or via short pendant oligopeptides, and related methods, compositions, and uses, particularly for use in appetite suppression and the treatment or prevention of diabetes or obesity.

Description

[Technical Field]

[0001] This application relates to compounds that are analogs of peptide YY (PYY) and are useful either alone or in combination with other agents, particularly in combination with GLP-1 analogs, to treat disorders such as diabetes and obesity. [Background technology]

[0002] According to the National Health and Nutrition Examination Survey (NHANES, 2011-2012), over two-thirds of U.S. adults are overweight or obese. 78% of men and 74% of women aged 20 years or older in the United States are either overweight or obese. Additionally, a large percentage of children in the United States are overweight or obese.

[0003] The causes of obesity are complex and multifactorial. There is increasing evidence that obesity is not a simple matter of self-control, but rather a complex disease involving appetite suppression and energy metabolism. Furthermore, obesity is associated with a variety of conditions related to increased morbidity and mortality in the population. The etiology of obesity has not been conclusively established, but genetic, metabolic, biochemical, cultural, and psychosocial factors are thought to contribute. Generally, obesity has been described as a condition in which excess body fat places an individual at risk for health.

[0004] There is strong evidence that obesity is associated with increased morbidity and mortality. Disease risk, such as cardiovascular disease risk and type II diabetes risk, increases independently of an increase in body mass index (BMI). In fact, this risk has been quantified as a 5 percent increase in heart disease risk for women and a 7 percent increase in heart disease risk for men for each point of BMI above 24.9 (see Kenchaiah et al., N.Engl.J.Med.347:305,2002; Massie, N.Engl.J.Med.347:358,2002).

[0005] Diabetes mellitus (DM) is a chronic syndrome characterized by impaired carbohydrate, protein, and fat metabolism due to insufficient insulin secretion or insulin resistance in target tissues. It occurs in two major forms: insulin-dependent diabetes mellitus (type 1 diabetes) and non-insulin-dependent diabetes mellitus (type 2 diabetes). Type 1 diabetes, or insulin-dependent diabetes mellitus (IDDM), is caused by the destruction of beta cells, resulting in insufficient levels of endogenous insulin. Type 2 diabetes, or non-insulin-dependent diabetes mellitus, results from both an inability of the body to respond to insulin and a relative deficiency in insulin production. According to the 2014 National Diabetes Statistics Report, approximately 28.9 million U.S. adults aged 20 years and older have diabetes (based on estimates from the 2009–2012 National Health and Nutrition Examination Survey and 2012 U.S. Census data). Among adults, 90–95% of cases of diabetes are type 2 diabetes.

[0006] There is strong evidence that weight loss in obese individuals reduces important disease risk factors. Even modest weight loss, such as 10% of initial body weight in both overweight and obese adults, is associated with reductions in risk factors such as hypertension, hyperlipidemia, and hyperglycemia. Significant weight loss has been shown to effectively treat type 2 diabetes (Lim et al, Diabetologia June 2011).

[0007] Although diet and exercise provide a simple way to reduce weight gain, overweight and obese individuals often cannot control these factors sufficiently to effectively reduce weight.Pharmacological treatment is available, and some weight-loss drugs that can be used as part of a comprehensive weight-loss program have been approved by the Food and Drug Administration.However, many of these drugs have serious adverse side effects.When less invasive methods are unsuccessful and patients are at high risk of obesity-related morbidity or mortality, weight-loss surgery is an option for carefully selected patients with severe clinical obesity.However, these treatments are risky and only suitable for use in a limited number of patients.It is not only obese subjects who want to lose weight.People who have a weight within the recommended range, for example, at the upper end of the recommended range, may want to reduce their weight to be closer to their ideal weight.Therefore, there remains a need for a drug that can be used to cause weight loss in overweight and obese subjects, as well as subjects with normal weight.

[0008] PYY is a 36-amino acid peptide produced by visceral L cells and found in highest concentrations in the large intestine and rectum. Two endogenous forms, PYY and PYY3-36, are released into the circulation. PYY3-36 is further produced by cleavage of the Tyr-Pro amino-terminal residue of PYY by the enzyme dipeptidyl peptidase IV (DPP-IV). PYY3-36 binds to the Y2 receptor of the Y family of receptors (De Silva and Bloom, Gut Liver, 2012, 6, pp. 10-20). Studies have shown that peripheral administration of PYY3-36 in rodents and humans results in significant inhibition of food intake, leading to the expectation that PYY analogs may be useful in treating conditions such as obesity (see, e.g., Batterham et al, Nature, 2002, 418, p650-654; Batterham et al, New England Journal of Medicine, 2003, 349, p941-948).

[0009] PYY is also involved in metabolic changes in subjects, and has been proposed as a treatment for type II diabetes, based on evidence that it can reverse impaired insulin and glucagon secretion in type II diabetes. The relationship between obesity and diabetes is complex, as being overweight increases the risk of diabetes, and having diabetes increases the likelihood of becoming overweight. PYY plays an increasingly recognized role in the connection between the two conditions.

[0010] WO2011 / 092473 and WO2012 / 101413 (Imperial Innovations Limited) disclose certain analogs of PYY. However, there remains a need for further compounds that have suitable properties to be effective as therapeutic agents for the treatment or prevention of disorders of energy metabolism, such as obesity and / or diabetes. [Prior art documents] [Patent documents]

[0011] [Patent Document 1] WO2011 / 092473 [Patent Document 2] WO2012 / 101413 Summary of the Invention [Problem to be solved by the invention]

[0012] Despite significant advances, the process of identifying substances useful as drugs remains complex and often unpredictable. To be useful as a therapeutic, a compound must possess an appropriate range of properties. In addition to having good efficacy at the biological target of interest, the compound must also have good in vivo pharmacokinetic properties, low toxicity, and an acceptable side effect profile. For example, even with commercially available drugs such as liraglutide, side effects can include nausea and vomiting, and there are growing concerns about thyroid cancer and pancreatitis. Therefore, there is still a need for additional compounds that are useful for treating diseases and conditions such as diabetes and obesity.For example, it would be desirable to identify peptides that have beneficial properties, such as improved activity profiles, and / or reduced side effects.If a compound reduces food intake less, it is expected that the compound will have fewer side effects, such as nausea.Alternatively, or in addition, it would be desirable to identify peptides that have these and other biological effects over a sustained period of time.Compounds with a longer duration of activity can be administered less frequently and at lower doses, which contributes to improved patient convenience, fewer side effects, and lower costs. [Means for solving the problem]

[0013] According to a first aspect of the present invention, there is provided a compound of formula I, II, or III, C-NH2 Formula I, BC-NH2 Formula II, ABC-NH2 Formula III, where C is the following peptide sequence: Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Pro8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Tyr2 0-Tyr21-Xaa22-Xaa23-Xaa24-Xaa25-Xaa26-Xaa27-Leu28-Asn29-Xaa30-Xaa31-Thr32-Arg33-Gln34-Arg35-Tyr36 [SEQ ID NO: 1] Xaa2 is Pro or Cys, Xaa3 is Lys or Ile substituted at its ε-amino group, Xaa4 is Lys or Lys substituted at its ε-amino group, Xaa5 is Pro or Cys, Xaa6 is Glu substituted at its γ-carboxylic acid group, Lys substituted at its ε-amino group, or Glu; Xaa7 is Lys substituted at its ε-amino group, Cys, Ala, or Cys substituted at its β-thiol group; Xaa9 is Lys substituted at its ε-amino group, Cys, Gly, or Cys substituted at its β-thiol group; Xaa10 is Glu substituted at its γ-carboxylic acid group, Lys substituted at its ε-amino group, Cys substituted at its β-thiol group, Lys, Glu, or Cys; Xaa11 is Lys, Asp, Gly, Asn, or Glu substituted at its ε-amino group; Xaa12 is Lys or Ala substituted at its ε-amino group, Xaa13 is Lys or Ser substituted at its ε-amino group, Xaa14 is Lys or Pro substituted at its ε-amino group, Xaa15 is Lys or Glu substituted at its ε-amino group, Xaa16 is Lys or Glu substituted at its ε-amino group, Xaa17 is Leu or Ile, Xaa18 is Lys, Asn, Leu, Ala, or Val substituted at its ε-amino group; Xaa19 is Lys, Arg, Lys, or His substituted at its ε-amino group; Xaa22 is Lys, Ala, or Ile substituted at its ε-amino group; Xaa23 is Lys, Ala, or Glu substituted at its ε-amino group; Xaa24 is Leu or Cys, Xaa25 is Lys or Arg substituted at its ε-amino group, Xaa26 is a Lys or His substituted at its ε-amino group, Xaa27 is Lys, Tyr, Phe, or Cys substituted at its ε-amino group; Xaa30 is Lys, Arg, Lys, or His substituted at its ε-amino group; Xaa31 is Val or Leu, B is a peptide residue selected from: Lys substituted at its ε-amino group, Ala, Tyr, Val, Ala, Ser, Gly, Lys, and Glu substituted at its α-amino group, A is the peptide sequence: Xaa51-Xaa52-Xaa53-Xaa54-Xaa55-Xaa56, [SEQ ID NO: 2] Xaa52-Xaa53-Xaa54-Xaa55-Xaa56, [SEQ ID NO: 3] Xaa53-Xaa54-Xaa55-Xaa56 [SEQ ID NO: 4] Xaa54-Xaa55-Xaa56, Xaa55-Xaa56, or Xaa56, Xaa51 is Glu or Glu substituted at its α-amino group, Xaa52 is substituted at its α-amino group with Glu, or substituted at its ε-amino group with Lys, Gly, or Tyr; Xaa53 is Glu substituted at its α-amino group, Gly, Ser, Asn, Gly, Glu, or Tyr substituted at its α-amino group; Xaa54 is Glu substituted at its γ-carboxylic acid group, Glu substituted at its α-amino group, Lys substituted at its ε-amino group, Ser substituted at its α-amino group, Asn substituted at its α-amino group, Ser, Gly, Glu, Tyr, Pro, Asn, or His; Xaa55 is Glu substituted at its γ-carboxylic acid group, Glu substituted at its α-amino group, Lys substituted at its ε-amino group, Ser substituted at its α-amino group, Gly, Ser, Glu, Pro, His, Asn, or Thr; Xaa56 is Lys substituted at its ε-amino group, Glu substituted at its γ-carboxylic acid group, Gly substituted at its α-amino group, Gly, Ser, Pro, His, Thr, Tyr, or Glu; The compound has a single substitution at one of the amino acid residues above, the substitution being selected from the following: (a) Based on the following formula: [ka] wherein the substituent is attached to the α-amino group of the substituted residue, or the substituted residue is Lys and the substituent is attached to the γ-amino group of the Lys residue; and R is a C8-C 28 an alkylene or alkenylene chain, and R1 is CO2H) (b) Z-Cys-S-, wherein Z is a group of the formula: [ka] (Wherein R is C8-C 28 an alkylene or alkenylene chain, and R1 is CO2H) (c) Z-Cys-S-, wherein Z is a group of the formula: [ka] (Wherein R is C8-C 28 an alkylene or alkenylene chain, and R1 is CO2H, or (d)XQ- wherein Q is a peptide sequence or a single amino acid residue selected from: Xaa65-Xaa64-Xaa63-Xaa62-Xaa61 [SEQ ID NO: 5], Xaa64-Xaa63-Xaa62-Xaa61 [SEQ ID NO: 6], Xaa63-Xaa62-Xaa61, Xaa62-Xaa61, and Xaa61, X is a group of the formula: [ka] where R is C-C 28 an alkylene or alkenylene chain, and R1 is CO2H; or a salt or derivative thereof is provided.

[0014] According to a second aspect of the present invention, there is provided a composition comprising a compound, derivative or salt of the first aspect of the present invention together with a pharmaceutically acceptable carrier and optionally a further therapeutic agent (e.g. an appetite suppressant that is a GLP-1 derivative).

[0015] According to a third aspect of the present invention there is provided a compound, derivative or salt of the first aspect of the invention, or a composition of the second aspect of the invention, for use as a medicament, for example for use in the prevention or treatment of diabetes, obesity, heart disease, stroke or non-alcoholic fatty liver disease, for improving insulin release in a subject, for improving carbohydrate metabolism in a subject, for improving the lipid profile of a subject, for improving carbohydrate tolerance in a subject, for reducing appetite, for reducing food intake, for reducing calorie intake, and / or for use as a cytoprotective agent.

[0016] According to a fourth aspect of the present invention, there is provided a method of treating or preventing a disease or disorder or other undesirable physiological condition in a subject, for example treating or preventing diabetes, obesity, heart disease, stroke, or non-alcoholic fatty liver disease, improving carbohydrate metabolism in a subject, improving the lipid profile in a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, reducing calorie intake, and / or providing cytoprotection in a subject, comprising administering a therapeutically effective amount of a compound, derivative, or salt of the first aspect of the invention, or a composition of the second aspect of the invention.

[0017] According to a fifth aspect of the present invention, there is provided a compound, derivative, or salt of the first aspect of the present invention, or a pharmaceutical composition of the second aspect of the present invention, for use in the prevention or treatment of diabetes, obesity, heart disease, stroke, and non-alcoholic fatty liver disease, for improving insulin release in a subject, for improving carbohydrate metabolism in a subject, for improving the lipid profile of a subject, for reducing appetite, for reducing food intake, for reducing calorie intake, for improving carbohydrate tolerance in a subject, and / or for use as a cytoprotective agent.

[0018] According to a sixth aspect of the present invention, there is provided a method of treating or preventing diabetes, obesity, heart disease, stroke, or non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, reducing calorie intake, and / or providing cytoprotection in a subject, the method comprising administering a therapeutically effective amount of a compound, derivative, or salt of the first aspect of the invention, or a composition of the second aspect of the invention.

[0019] According to a seventh aspect of the present invention there is provided use of a compound, derivative or salt of the first aspect of the present invention for the manufacture of a medicament for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, for improving insulin release in a subject, for improving carbohydrate metabolism in a subject, for improving the lipid profile of a subject, for improving carbohydrate tolerance in a subject, for reducing appetite, for reducing food intake, for reducing calorie intake and / or for use as a cytoprotective agent.

[0020] According to an eighth aspect of the present invention, there is provided a method of inducing weight loss or preventing weight gain in a subject for cosmetic purposes, the method comprising administering an effective amount of a compound, derivative, or salt of the first aspect of the invention, or a composition of the second aspect of the invention.

[0021] The present invention is based on the discovery that PYY analogs in which specific amino acid residues are deleted and / or substituted can also be administered to a subject to cause reduced food intake, reduced calorie intake, reduced appetite, and altered energy metabolism. In many cases, the PYY analogs of the present invention exhibit improved efficacy and / or a longer duration of action and / or fewer side effects than native PYY.

[0022] The compounds of the present invention are also particularly suitable for use in combination therapy with GLP-1 receptor agonists.This is because PYY and GLP-1 analogs are widely compatible and have similar chemical properties, which makes it possible to formulate them together and conveniently administer them as a single injection.In addition, PYY analogs and GLP-1 analogs inhibit appetite through different, separate mechanisms, so patients receiving combination therapy are less likely to "withdraw" from the desired drug effect than when treated with either drug alone.Finally, the different mechanisms of action allow for additive or synergistic effects on appetite suppression, resulting in a more powerful therapy. [Brief explanation of the drawings]

[0023] [Figure 1-1] 1 is a table listing the amino acid sequences of several PYY analogs relevant to certain preferred embodiments of the present invention. The naturally occurring sequence of human PYY (hPYY) is included in the first line for reference. [Figure 1-2] This is a continuation of Figure 1-1. [Figure 1-3] This is a continuation of Figure 1-2. [Figure 1-4] This is a continuation of Figure 1-3. [Figure 1-5] This is a continuation of Figure 1-4. [Figure 1-6] This is a continuation of Figure 1-5. [Figure 1-7] This is a continuation of Figure 1-6. [Figure 1-8] This is a continuation of Figure 1-7. [Figure 1-9] This is a continuation of Figure 1-8. [Figure 1-10] This is a continuation of Figure 1-9. [Figure 1-11] This is a continuation of Figure 1-10. [Figure 1-12] This is a continuation of Figure 1-11. [Figure 1-13] This is a continuation of Figure 1-12. [Figure 1-14] This is a continuation of Figure 1-13. [Figure 1-15] This is a continuation of Figure 1-14. [Figure 1-16] This is a continuation of Figure 1-15. [Figure 2-1] 1 is a table showing the results of human cAMP inhibition studies and solubility scores for exemplary compounds of the invention and certain control or reference compounds, as well as the results of dietary studies in rats administered exemplary compounds of the invention or certain control or reference compounds. [Figure 2-2] This is a continuation of Figure 2-1. [Figure 2-3] This is a continuation of Figure 2-2. [Figure 2-4] This is a continuation of Figure 2-3. [Figure 2-5] This is a continuation of Figure 2-4. [Figure 2-6] This is a continuation of Figure 2-5. [Figure 2-7] This is a continuation of Figure 2-6. [Figure 2-8] This is a continuation of Figure 2-7. DETAILED DESCRIPTION OF THE INVENTION

[0024] Derivatizations in the amino acid sequences shown in Figure 1 are indicated by "*n." These derivatives are described in Table 1 below. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] Note that, as used above, the symbol "γGlu" denotes a Glu residue that is attached to its adjacent amino acid residue not through the usual eupeptide bond, but through an isopeptide bond between the α-amino group of the adjacent amino acid residue and the carboxylic acid group on the γ-carbon (C-4) of Glu. [Sequence table] This application is accompanied by a machine-readable sequence listing. The invention in certain embodiments encompasses the sequences of the sequence listing, peptides comprising or consisting of those sequences, and all related uses, methods, and products described therein.

[0025] definition In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms are provided:

[0026] Animal: Living multi-cellular vertebrate organisms, a classification that includes, for example, mammals and birds. The term mammal includes both human and non-human mammals. Similarly, the term "subject" includes both human and animal subjects.

[0027] Appetite: The natural desire or craving for food. In one embodiment, appetite is measured by a survey to assess the desire for food. Increased appetite generally results in increased eating behavior.

[0028] Appetite suppressant: A compound that reduces the desire for food. Over-the-counter appetite suppressants include, but are not limited to, amfepramone (diethylpropion), phentermine, mazindol, phenylpropanolamine fenfluramine, dexfenfluramine, and fluoxetine.

[0029] Body Mass Index (BMI): A mathematical formula for measuring obesity, sometimes called the Quetelet index. BMI is calculated by multiplying weight (kg) by height. 2 (m 2The current standard for both men and women that is accepted as "normal" is 20-24.9 kg / m 2 In one embodiment, the BMI is 25 kg / m 2 A BMI of 25 to 29.9 kg / m can be used to identify obese subjects. Grade I obesity is defined as 25 to 29.9 kg / m 2 Grade II obesity corresponds to a BMI of 30-40 kg / m 2 and grade III obesity corresponds to a BMI of 40 kg / m 2 (Jequier, Am. J Clin. Nutr. 45:1035-47, 1987). Ideal body weight varies among races and individuals based on height, build, bone structure, and sex.

[0030] Conservative substitution: The replacement of an amino acid residue in a polypeptide with another biologically similar residue. The term "conservative variation" also includes the use of substituted amino acids, i.e., amino acids in which one or more atoms are replaced with another atom or group, in place of the parent amino acid, provided that the polypeptide retains its activity or that antibodies generated against the substituted polypeptide also immunoreact with the unsubstituted polypeptide. Exemplary, but not limited to, conservative substitutions include the substitution of the aliphatic amino acids Ala, Val, Leu, and Ile for each other; the interchange of the hydroxyl-containing residues Ser and Thr, the interchange of the acidic residues Asp and Glu, the interchange of the amide-containing residues Asn and Gln, the interchange of the basic residues Lys and Arg, the interchange of the aromatic residues Phe and Tyr, and the interchange of the small amino acids Ala, Ser, Thr, Met, and Gly. Further conservative substitutions include the substitution of an amino acid with another similar spatial or steric configuration, for example, the interchange of Asn with Asp or the interchange of Gln with Glu. [Table 2]

[0031] Non-conservative substitution: The replacement of an amino acid residue in a polypeptide with another residue that is not biologically similar, for example, the replacement of an amino acid residue with another residue that has a substantially different charge, a substantially different hydrophobicity, or a substantially different spatial or steric configuration.

[0032] Diabetes: The failure of cells to transport endogenous glucose across their membranes due to either endogenous insulin deficiency and / or defective insulin sensitivity. Diabetes is a chronic syndrome in which carbohydrate, protein, and fat metabolism are impaired due to insufficient insulin secretion or insulin resistance in target tissues. Diabetes occurs in two major forms: insulin-dependent diabetes mellitus (IDDM, type I) and non-insulin-dependent diabetes mellitus (NIDDM, type II), which differ in etiology, pathogenesis, genetics, age of onset, and treatment.

[0033] The two major forms of diabetes are characterized by the inability to deliver insulin in the amounts and at the precise times required for the control of glucose homeostasis. Type I diabetes, or insulin-dependent diabetes mellitus (IDDM), is caused by the destruction of beta cells, resulting in insufficient levels of endogenous insulin. Type II diabetes, or non-insulin-dependent diabetes, results from both an inability of the body to respond to insulin and a relative deficiency in insulin production.

[0034] Food intake: The amount of food consumed by an individual. Food intake can be measured by volume or weight. For example, food intake can be the total amount of food ingested by an individual. Or, food intake can be the amount of protein, fat, carbohydrates, cholesterol, vitamins, minerals, or any other dietary component of an individual. "Protein intake" refers to the amount of protein consumed by an individual. Similarly, "fat intake," "carbohydrate intake," "cholesterol intake," "vitamin intake," and "mineral intake" refer to the amount of protein, fat, carbohydrate, cholesterol, vitamin, or mineral consumed by an individual.

[0035] Normal daily diet: The average food intake of an individual of a given race. A standard daily diet can be expressed in terms of calorie intake, protein intake, carbohydrate intake, and / or fat intake. A human standard daily diet generally includes: about 2,000, about 2,400, or about 2,800 calories or significantly more. Furthermore, a human standard daily diet generally includes about 12 g to about 45 g of protein, about 120 g to about 610 g of carbohydrates, and about 11 g to about 90 g of fat. A low-calorie diet is no more than about 85%, preferably no more than about 70%, of a human individual's standard calorie intake.

[0036] In animals, calorie and nutritional requirements vary depending on the species and size of the animal. For example, in cats, the total calorie intake per pound and the distribution of protein, carbohydrate, and fat vary depending on the age and reproductive status of the cat. However, a general guideline for cats is 40 cal / lb / day (18.2 cal / kg / day). Approximately 30% to 40% should be protein, about 7% to 10% should be carbohydrate, and about 50% to 62.5% should come from fat intake. Those skilled in the art can easily identify the normal daily diet of an individual of any species.

[0037] Obesity: A condition in which excess body fat can put an individual at health risk (see Barlow and Dietz, Pediatrics 102:E29, 1998; National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Obes. Res. 6(suppl. 2):51S-209S, 1998). Excess body fat is the result of an imbalance between energy intake and energy expenditure. For example, body mass index (BMI) may be used to assess obesity. In one commonly used convention, a BMI of 25.0 kg / m 2 ~29.9kg / m 2 is overweight with a BMI of 30 kg / m 2 The above BMI indicates obesity.

[0038] Another convention uses waist circumference to assess obesity. In this convention, a waist circumference of 102 cm or greater is considered obese in men, and a waist circumference of 89 cm or greater is considered obese in women. Compelling evidence indicates that obesity affects both an individual's morbidity and mortality. For example, obese individuals are at increased risk of heart disease, non-insulin-dependent (type II) diabetes, hypertension, stroke, cancer (e.g., endometrial, breast, prostate, and colon cancer), dyslipidemia, gallbladder disease, sleep apnea, subfertility, and osteoarthritis, among others (see Lyznicki et al., Am. Fam. Phys. 63:2185, 2001).

[0039] Overweight: An individual who is heavier than their ideal body weight. An overweight individual may be obese, but is not necessarily obese. For example, an overweight individual is any individual who desires to lose weight. In one convention, an overweight individual is one who weighs less than 25.0 kg / m 2 ~29.9kg / m 2 The individual has a BMI of

[0040] PEGylated and PEGylation: The process of reacting a poly(alkylene glycol), preferably an activated poly(alkylene glycol), to form a covalent bond. A promoter, such as an amino acid, e.g., lysine, may be used. While "PEGylation" is often performed using poly(ethylene glycol) or a derivative thereof, such as methoxypoly(ethylene glycol), the term as used herein is not limited to the use of methoxypoly(ethylene glycol) but also includes the use of any other useful poly(alkylene glycol), e.g., poly(propylene glycol).

[0041] pI: pI is an abbreviation for isoelectric point. An alternative abbreviation sometimes used is IEP. IEP is the pH at which a particular molecule has no net charge. At a pH below its pI, a protein or peptide has a net positive charge. At a pH above its pI, a protein or peptide has a net negative charge. Proteins and peptides can be separated according to their isoelectric points using a technique called isoelectric focusing, which is an electrophoretic method that utilizes a pH gradient contained in a polyacrylimide gel.

[0042] Peptide YY (PYY): As used herein, the term PYY refers to peptide YY polypeptide, a hormone secreted into the blood by cells lining the lower small intestine (ileum) and colon. Naturally occurring wild-type PYY sequences for various species are shown in Table 2. [Table 3-1] [Table 3-2]

[0043] Peripheral administration: Administration outside the central nervous system. Peripheral administration does not include direct administration to the brain. Peripheral administration includes, but is not limited to, intravascular, intramuscular, subcutaneous, inhalation, oral, rectal, transdermal, or intranasal administration.

[0044] Polypeptide: A polymer of amino acid residues whose monomers are linked together through amide bonds. When the amino acids are α-amino acids, either the L-optical isomer or the D-optical isomer can be used, with the L-isomer being preferred. As used herein, the term "polypeptide" or "protein" encompasses any amino acid sequence, including modified sequences such as glycoproteins. The term "polypeptide" strictly encompasses naturally occurring proteins as well as recombinantly or synthetically produced proteins. The term "polypeptide fragment" refers to a portion of a polypeptide, e.g., a fragment that exhibits at least one useful sequence in receptor binding. The term "functional fragment of a polypeptide" refers to all fragments of a polypeptide that retain the activity of the polypeptide. Biologically functional peptides can also include fusion proteins, in which the peptide of interest is fused to another peptide that does not reduce its desired activity.

[0045] Subcutaneous administration: Subcutaneous administration is the administration of a substance into the subcutaneous layer of fat found between the dermis and deeper tissues of the skin. Subcutaneous administration may be by injection, for example, using a hypodermic needle fitted with a syringe or a "pen"-type injection device. Other administration methods, such as microneedles, may also be used. Injections using a hypodermic needle typically involve some degree of pain for the benefit of the recipient. Such pain can be suppressed by the use of local anesthetics or analgesics. However, the most commonly used method to reduce the perceived pain of injection is simply to distract the subject immediately before and during the injection. Pain can be minimized by using a relatively small gauge hypodermic needle, injecting a relatively small amount of substance, and avoiding overly acidic or alkaline compositions, which can cause the subject to experience a "stinging" sensation at the injection site. Compositions with a pH between pH 4 and pH 10 are generally considered to be tolerably comfortable.

[0046] Therapeutically effective amount: A dose sufficient to prevent progression or cause regression of a disorder, or to alleviate the signs or symptoms of a disorder, or to achieve a desired result. In some embodiments, a therapeutically effective amount of a compound of the invention is an amount sufficient to inhibit or stop weight gain, or to reduce appetite, or to reduce caloric or food intake.

[0047] Sequence Listing Amino acid sequences herein are presented with the N-terminus at the left, and when sequences are arranged across multiple lines, the N-terminus is at the top left. Unless otherwise specified, amino acid residues in a sequence are L-amino acids.

[0048] Compounds of the Invention Compounds related to all aspects of the present invention are PYY analogs having a primary amino acid sequence of 30-42 residues derived (through residue substitutions, deletions, and additions) from a native PYY sequence (preferably from a native human sequence), where the amino acid residues of the primary sequence are derivatized by the attachment of a substituent derived from a fatty diacid. This substituent can be a fatty diacid attached directly to a residue of the primary amino acid sequence, or can comprise a short (e.g., 1-6 residue) peptide onto which the fatty diacid is carried.

[0049] According to all aspects of the present invention, the substituents are: (a) Based on the following formula: [ka] wherein the substituent is attached to the α-amino group of the substituted residue, or the substituted residue is Lys and the substituent is attached to the γ-amino group of the Lys residue; and R is a C8-C 28 an alkylene or alkenylene chain, and R1 is CO2H; (b) Z-Cys-S-, wherein Z is a group of the formula: [ka] (Wherein R is C8-C 28 an alkylene or alkenylene chain, and R1 is CO2H; (c) Z-Cys-S-, wherein Z is a group of the formula: [ka] (Wherein R is C8-C 28 an alkylene or alkenylene chain, and R1 is CO2H, or (d)XQ- wherein Q is a peptide sequence or a single amino acid residue selected from: Xaa65-Xaa64-Xaa63-Xaa62-Xaa61 [SEQ ID NO: 5], Xaa64-Xaa63-Xaa62-Xaa61 [SEQ ID NO: 6], Xaa63-Xaa62-Xaa61, Xaa62-Xaa61, and Xaa61, X is a group of the formula: [ka] where R is C-C 28 an alkylene or alkenylene chain, and R1 is CO2H.

[0050] According to some embodiments, the substituents may preferably be selected from one of the derivatives set forth in Table 1 above.

[0051] Option (a) above represents a situation in which the substituent is a fatty diacid directly attached to the primary peptide sequence. According to certain preferred embodiments, the fatty diacid is a hexadecadioic acid, an octadecadioic acid, or an eicosane diacid (i.e., R is 14, 16, or 18, respectively, with additional carbon atoms present in the R moiety and the C=O group, resulting in 16, 18, or 20 carbon atoms in the diacid chain, respectively). It is understood that attachment of such a diacid is via one of the two CO(OH) groups of the acid to an NH group on the primary peptide sequence. The NH may be a non-α-NH group (e.g., the ε-NH group of the side chain of a lysine residue). Alternatively, it may be via an α-NH group at the N-terminus of the primary peptide sequence. According to certain embodiments, attachment of the substituent is facilitated by substitution of a naturally occurring PYY amino acid residue with a residue having an NH-containing side chain (e.g., Arg or Lys, most preferably Lys).

[0052] Option (b) above represents a situation in which the substituent comprises a fatty diacid-derived moiety and is attached to the primary peptide sequence via a Glu residue. According to certain preferred embodiments, the fatty diacid is hexadecadioic acid, octadecadioic acid, or eicosane diacid (i.e., R is 14, 16, or 18, respectively, with additional carbon atoms present in the R moiety and the C=O group, resulting in 16, 18, or 20 carbon atoms in the diacid chain, respectively). It is understood that attachment of such diacids is via one of the acid's two CO(OH) groups to the α-NH group of the Glu residue. The Glu residue is, in turn, attached to the primary peptide sequence via its α-CO(OH) group, which is attached to an NH group on the primary peptide sequence. The NH may be a non-α-NH group (e.g., the ε-NH group of the side chain of a lysine residue). Alternatively, it may be via the α-NH group at the N-terminus of the primary peptide sequence. According to certain embodiments, attachment of the substituent is facilitated by substitution of a naturally occurring PYY amino acid residue with a residue having an NH2-containing side chain (eg, Arg or Lys, most preferably Lys).

[0053] Option (c) above represents a situation in which the substituent comprises a fatty diacid-derived moiety attached to the dipeptide Glu-Cys via a Glu residue. According to certain preferred embodiments, the fatty diacid is hexadecadioic acid, octadecadioic acid, or eicosane diacid (i.e., R is 14, 16, or 18, respectively, with additional carbon atoms present in the R moiety and the C=O group, resulting in 16, 18, or 20 carbon atoms in the diacid chain, respectively). The substituent can be attached by providing sufficient reducing conditions for the formation of an -SS- bridge between the Cys residue of the dipeptide and the Cys residue of the primary peptide sequence. According to certain embodiments, attachment of the substituent is facilitated by substitution of a naturally occurring PYY amino acid residue with a Cys residue.

[0054] Derivative binding According to the present invention, a substituent may be attached at any of the positions in the primary peptide sequence permitted by the claims, i.e., one of positions Xaa51, Xaa52, Xaa53, Xaa54, Xaa55, Xaa56, Xaa3, Xaa4, Xaa6, Xaa7, Xaa9, XaalO, Xaal 1, Xaal2, Xaal3, Xaal4, Xaal5, Xaal6, Xaal8, Xaal9, Xaa22, Xaa23, Xaa25, Xaa26, Xaa27, or Xaa30. Preferred positions are selected from Xaa51, Xaa52, Xaa53, Xaa54, Xaa55, Xaa56, Xaa6, Xaa7, Xaa9, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa18, Xaa19, Xaa26, or Xaa30, e.g., Xaa6, Xaa Xaa26, or Xaa30, or selected from Xaa7, Xaa9, or Xaa10, or from Xaa7, Xaa9, Xaa10, or Xaa30.

[0055] The substituents are at positions Glu51, Glu52, Glu53, Glu54, Glu55, Glu56, Glu3, Glu4, Glu6, Glu7, Glu9, Glu10, Glu11, Glu12, Glu13, Glu14, Glu15, Glu16, Glu18, Glu19, Glu22, Glu23, Glu25, Glu26, Glu27, Lys51, Lys52 , Lys53, Lys54, Lys55, Lys56, Lys3, Lys4, Lys6, Lys7, Lys9, Lys10, Lys11, Lys12, Lys13, Lys14, Lys15, Lys16, Lys18, Lys19, Lys22, Lys23, Lys25, Lys26, Lys27, or Lys30. Preferred positions are Glu51, Glu52, Glu53, Glu54, Glu55, Glu56, Glu6, Glu7, Glu9, Glu10, Glu11, Glu12, Glu13, Glu14, Glu15, Glu16, Glu18, Glu19, Glu26, Lys51, Lys52, Lys53, Lys54, Lys55, Lys56, Lys6, Lys7, and selected from Lys9, Lys10, Lys11, Lys12, Lys13, Lys14, Lys15, Lys16, Lys18, Lys19, Lys26, or Lys30, e.g., Glu6, Glu7, Glu9, Glu10, Glu11, Glu12, Glu13, Glu14, Glu15, Glu16, Glu18, Glu19, Glu26, or Lys 30, Lys6, Lys7, Lys9, Lys10, Lys11, Lys12, Lys13, Lys14, Lys15, Lys16, Lys18, Lys19, Lys26, or Lys30, or selected from Glu7, Glu9, Glu10, Lys7, Lys9, Lys10, or Lys30.In other embodiments, the positions are Glu51, Glu52, Glu53, Glu54, Glu55, Glu56, Glu6, Glu7, Glu9, Glu10, Glu11, Glu12, Glu13, Glu14, Glu15, Glu16, Glu18, Glu19, Glu26, Lys51, Lys52, Lys53, Lys54, Lys55, Lys56, Lys6, Lys7, Lys9, Lys10, Lys11, Lys12, Lys13, Lys14, Lys15, Lys16, Lys18, Lys19, or Lys26, e.g., selected from Glu6, Glu7, Glu9, Glu10, Glu11, Glu12, Glu13, Glu14, Glu15, Glu16, Glu18, Glu19, or Glu26, Lys6, Lys7, Lys9, Lys10, Lys11, Lys12, Lys13, Lys14, Lys15, Lys16, Lys18, Lys19, or Lys26, or selected from Glu7, Glu9, Glu10, Lys7, Lys9, or Lys10.

[0056] According to certain preferred embodiments, the compounds according to the invention have the additional characteristics listed below: 1, Xaa2 is Pro, 2, Xaa3 is Ile; 3. Xaa4 is Lys; 4. Xaa5 is Pro, 5, Xaa6 is Lys or Glu substituted at its ε-amino group; 6, Xaa7 is Lys or Ala substituted at its ε-amino group; 7, Xaa9 is Lys or Gly substituted at its ε-amino group; 8, Xaa10 is Lys or Glu substituted at its ε-amino group; 9, Xaa11 is Lys, Asp, Gly, or Glu substituted at its ε-amino group; 10, Xaa12 is Lys or Ala substituted at its ε-amino group; 12, Xaa13 is Lys or Ser substituted at its ε-amino group; 13, Xaa14 is Lys or Pro substituted at its ε-amino group; 14, Xaa15 is Lys or Glu substituted at its ε-amino group; 15, Xaa16 is Lys or Glu substituted at its ε-amino group; 16, Xaa17 is Leu or Ile; 17, Xaa18 is Lys, Leu, or Val substituted at its ε-amino group; 18, Xaa19 is Arg, Lys, or His; 19, Xaa22 is Ala or Ile, 20, Xaa23 is Ala or Glu; 21, Xaa24 is Leu, 22, Xaa25 is Arg, 23, Xaa26 is Lys or His substituted at its ε-amino group; 24, Xaa27 is Phe; 25, Xaa is Lys or His substituted at its ε-amino group; 26, Xaa31 is Val or Leu, and at least one of the following applies.

[0057] According to some embodiments, one, two, three, four, five, six, seven, eight, nine, or ten of the above criteria 1-26 apply (provided that the compound contains only a single fatty diacid-derived substituent). According to other embodiments, all of the above criteria 1-25 apply (provided that the compound contains only a single fatty diacid-derived substituent). According to other embodiments, all of the above criteria 1-25 apply (provided that the compound contains only a single fatty diacid-derived substituent), except that no more than one or no more than two of residues 2-36 are subject to conservative substitution (provided that the compound contains only a single fatty diacid-derived substituent).

[0058] Further derivatization In addition to the attachment of the diacid moiety, either directly or together with the short peptide moiety described herein, the compounds of the present invention may incorporate further derivatization selected from amidation, glycosylation, carbamylation, acylation, sulfation, phosphorylation, cyclization, lipidation, PEGylation, and fusing to another peptide or protein to form a fusion protein. In many embodiments, it is particularly preferred that the primary peptide chains of the compounds of the present invention be amidated at their C-terminus. Such modifications are very common in nature, with approximately half of naturally occurring peptides, including PYY, being susceptible to amidation at their C-terminus. The present invention encompasses all of the general and specific sequences disclosed herein, including amidation, if present, at the C-terminus of the primary peptide sequence, in both amidated and non-amidated form in the sequence listing and figures.

[0059] N-terminus of the primary sequence. According to certain preferred embodiments, the compounds of the invention have formula I (i.e., the primary peptide sequence begins at Xaa2). Also preferred are compounds of formula II, in which B is Lys (preferably substituted according to the present disclosure).

[0060] According to another embodiment, the compound of the invention is according to formula III, wherein A is the following peptide sequence: Xaa51-Xaa52-Xaa53-Xaa54-Xaa55-Xaa56 [SEQ ID NO: 38], Xaa52-Xaa53-Xaa54-Xaa55-Xaa56 [SEQ ID NO: 39], Xaa53-Xaa54-Xaa55-Xaa56 [SEQ ID NO: 40], Xaa54-Xaa55-Xaa56, Xaa55-Xaa56, or Xaa56, Xaa51 is a Glu substituted at its α-amino group, Xaa52 is substituted at its α-amino group with Glu or substituted at its ε-amino group with Lys; Xaa53 is Glu or Gly substituted at its α-amino group, Xaa54 is Ser or Pro, Xaa55 is Lys, Gly, or Pro substituted at its ε-amino group; Xaa56 is Lys substituted at its ε-amino group, Glu, Ser, Pro, or Thr substituted at its γ-carboxylic acid group.

[0061] When the compounds of the invention are according to Formula III, it is preferred that B is Gly, Ser, or Tyr and A is a substituted Lys or a substituted Glu.

[0062] According to a particular embodiment, the substituent is preferably attached to the ε-amino group of the Lys residue at position Xaa10.

[0063] When Q is present according to Formula I, II, or III, it is preferably Gly65-Ser64-Gly63-Ser62-Gly61 [SEQ ID NO: 41]. Alternatively, Q can be Xaa64-Xaa63-Xaa62-Xaa61 [SEQ ID NO: 42]; Xaa64 is Gly, Ser, or Thr, Xaa63 is Ser, Thr, or Gly, Xaa62 is Gly or Ser, and Xaa61 is Ser, Thr, Gly, or Asp. Alternatively, Q can be Xaa63-Xaa62-Xaa61, where Xaa63 is Gly, Pro, Glu, Ser, or Thr, Xaa62 is Ser, Thr, or Gly, and Xaa61 is Gly or Thr. Alternatively, Q can be Xaa62-Xaa61, where Xaa62 is Ser, Gly, Tyr, Thr, or Asn, and Xaa61 is Gly, Thr, His, or Ser. Alternatively, Q can be Xaa61 and Zaa61 is Gly, Glu, Lys, Asn, or Gln. Alternatively, Q can be Gly63-Ser62-Gly61. Alternatively, Q can be Glu63-Gly62-Ser61. Alternatively, Q can be Glu63-Gly62-Thr61. Alternatively, Q can be Asn62-His61. Alternatively, Q can be Glu61. Alternatively, Q can be Gly61.

[0064] Substituent Bonds It should be noted that all compounds of all aspects of the present invention contain a single substituent derived from a fatty diacid in accordance with the present invention, which moiety may be attached to the A, B, or C moiety of the compound of the present invention.

[0065] In accordance with the present invention, substituents are attached (e.g., via a condensation reaction or an -SS- bridge) to groups on the indicated amino acid residues of the primary peptide sequence, which groups are, in accordance with the present invention, where appropriate, designated using the IUPAC numbering convention for carbon atoms, as shown below using the amino acids Glu and Lys, respectively, as examples. [ka]

[0066] Cyclic compounds. The compounds of the present invention may have a substituent bonded to the Cys residue via an -SS-bridge as described above.Alternatively or additionally, the primary peptide sequence may contain two or more additional Cys residues with an -SS-bridge between them.Such residues are preferably located at positions Xaa2, Xaa3, Xaa5, Xaa24, or Xaa27, allowing an -SS-bridge between Cys2 or Cys5 and Cys24 or Cys27.If the substituent is not bonded to a Cys residue, it is bonded to another residue as described herein.According to certain embodiments, such cyclic compounds are not preferred.

[0067] The compounds, derivatives or salts according to the present invention may be any of the following: A, B of formula II or III is a Lys residue, optionally substituted at its ε-amino group, B, Xaa2 is Pro, C, Xaa2-Xaa3-Xaa4-Xaa5-Xaa6 [SEQ ID NO: 43] is Pro2-Ile3-Lys4-Pro5-Glu6 [SEQ ID NO: 44]; D, Xaa7 is Lys or Ala substituted at its ε-amino group; E, Xaa9 is Lys or Gly substituted at its ε-amino group; F, Xaa10 is Lys or Glu substituted at its ε-amino group; G, Xaa11 is Gly, Asn, or Glu; H, Xaa12-Xaa13-Xaa14-Xaa15-Xaa16 [SEQ ID NO: 45] is Ala12-Ser13-Pro14-Glu15-Glu16 [SEQ ID NO: 46]; I, Xaa18 is Asn, Leu, Ala, or Val, preferably Leu; J, Xaa19 is His, K, Xaa22 is Ala or Ile, L, Xaa23 is Ala or Glu; M, Xaa24 is Leu or Cys; N, Xaa25 is Arg, O, Xaa26 is His, P, Xaa27 is Phe.

[0068] Preferably, the compound has a combination of features H, I, J, K, L, M, N, O, and P, optionally further combined with feature C and one of features D, E, or F. Other preferred feature combinations include the following: B, D, E, F, G, H, I, J, K, L, M, N, O, and P C, D, E, F, G, H, I, J, K, L, M, N, O, and P B, C, E, F, G, H, I, J, K, L, M, N, O, and P B, C, D, F, G, H, I, J, K, L, M, N, O, and P B, C, D, E, G, H, I, J, K, L, M, N, O, and P B, C, D, E, F, H, I, J, K, L, M, N, O, and P B, C, D, E, F, G, I, J, K, L, M, N, O, and P B, C, D, E, F, G, H, J, K, L, M, N, O, and P B, C, D, E, F, G, H, I, K, L, M, N, O, and P B, C, D, E, F, G, H, I, J, L, M, N, O, and P B, C, D, E, F, G, H, I, J, K, M, N, O, and P B, C, D, E, F, G, H, I, J, K, L, N, O, and P B, C, D, E, F, G, H, I, J, K, L, M, O, and P B, C, D, E, F, G, H, I, J, K, L, M, N, and P B, C, D, E, F, G, H, I, J, K, L, M, N, and O A, B, D, E, F, G, H, I, J, K, L, M, N, O, and P A, C, D, E, F, G, H, I, J, K, L, M, N, O, and P A, B, C, E, F, G, H, I, J, K, L, M, N, O, and P A, B, C, D, F, G, H, I, J, K, L, M, N, O, and P A, B, C, D, E, G, H, I, J, K, L, M, N, O, and P A, B, C, D, E, F, H, I, J, K, L, M, N, O, and P A, B, C, D, E, F, G, I, J, K, L, M, N, O, and P A, B, C, D, E, F, G, H, J, K, L, M, N, O, and P A, B, C, D, E, F, G, H, I, K, L, M, N, O, and P A, B, C, D, E, F, G, H, I, J, L, M, N, O, and P A, B, C, D, E, F, G, H, I, J, K, M, N, O, and P A, B, C, D, E, F, G, H, I, J, K, L, N, O, and P A, B, C, D, E, F, G, H, I, J, K, L, M, O, and P A, B, C, D, E, F, G, H, I, J, K, L, M, N, and P A, B, C, D, E, F, G, H, I, J, K, L, M, N, and O

[0069] Preferred specific compounds include those listed in Figure 1, and also compounds that differ from those disclosed in Figure 1 by single or double conservative amino acid residue changes at positions that are not substituted.

[0070] Particularly preferred compounds include Y1596, Y1597, Y1603, Y1606, Y1619, Y1621, Y1622, Y1631, Y1632, Y1638, Y1642, Y1644, Y1650, Y1660, Y1661, Y1662, Y1663, Y1665, Y1674, Y1679, Y1683, Y1684, Y1685, Y1686, Y1687, Y1688, Y1689, Y1690, Y1691, Y1692, Y1693, Y1694, Y1695, Y1696, Y1697, Y1698, Y1699, Y1700, Y1701, Y1702, Y1703, Y1704, Y1705, Y1706, Y1707, Y1708, Y1709, Y1710, Y1711, Y1712, Y1713, Y1714, Y1715, Y1716, Y1717, Y1718, Y1719, Y1820, Y1821, Y1822, Y1823, Y1824, Y1825, Y1826, Y1827, Y1828, Y1829, Y1830, Y1831, Y1832, Y1833, Y1834, Y1835, Y1836, Y1837, Y1838, Y1840, Y1841, Y1842, Y1844, Y1850, Y1851, Y1852, Y1853, Y 95, Y1726, Y1733, Y1734, Y1735, Y1739, Y1740, Y1741, Y1746, Y1747, Y1748, Y1749, Y1751, Y1753, Y1754, Y1764, Y1768, Y1769, Y1770, Y1771, Y1772, Y1773, Y1775, Y1776, Y1777, Y177 8, Y1779, Y1781, Y1782, Y1783, Y1784, Y1785, Y1786, Y1787, Y1788, Y1789, Y1790, Y1791, Y 1792, Y1793, Y1794, Y1795, Y1796, Y1797, Y1798, Y1799, Y, Y1800, Y1801, Y1802, Y1803, Y18 04, Y1805, Y1806, Y1807, Y1816, Y1818, Y1819, Y1820, Y1821, Y1822, Y1823, Y1824, Y1825, Y1826, and Y1827, and also compounds that differ from those compounds by single or double conservative amino acid residue changes at the unsubstituted positions.

[0071] salt Salts of the PYY analog compounds of the present invention that are suitable for use in medicines are those in which the counterion is pharmaceutically acceptable. However, salts having pharmaceutically unacceptable counterions are also within the scope of the present invention, for example, for use as intermediates in the preparation of the PYY analogs of the present invention, and their pharmaceutically acceptable salts and / or derivatives.

[0072] Suitable salts according to the present invention include salts formed with organic or inorganic acids or bases. Pharmaceutically acceptable acid addition salts include those formed with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, citric acid, tartaric acid, acetic acid, phosphoric acid, lactic acid, pyruvic acid, acetic acid, trifluoroacetic acid, succinic acid, perchloric acid, fumaric acid, maleic acid, glycolic acid, lactic acid, salicylic acid, oxaloacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and isethionic acid. Other acids, such as oxalic acid, may be useful as intermediates in obtaining the compounds of the present invention.

[0073] Pharmaceutically acceptable salts with bases include ammonium salts, alkali metal salts such as potassium salts and sodium salts, alkaline earth metal salts such as calcium salts and magnesium salts, and salts with organic bases such as dicyclohexylamine and N-methyl-D-glucamine.

[0074] solvate Those skilled in the art of organic chemistry will understand that many organic compounds can form complexes with solvents with which they react or from which they are precipitated or crystallized. These complexes are known as "solvates." For example, complexes with water are known as "hydrates." Solvates, such as hydrates, exist when a drug substance incorporates a solvent, such as water, into the crystal lattice in either stoichiometric or non-stoichiometric amounts. Drug substances are routinely screened for the presence of hydrates, as they may encounter solvent incorporation at any stage of the drug manufacturing process or during storage of the drug substance or dosage form. Solvates are discussed in more detail in S. Byrn et al., Pharmaceutical Research 12(7), 1995, 954-954, and Water-Insoluble Drug Formulation, 2000, incorporated herein by reference. nded. R. Liu, CRC Press, page 553. Therefore, it will be understood by those skilled in the art that the PYY analogs of the present invention, and derivatives and / or salts thereof, may exist in the form of solvates. Solvates of the PYY analogs of the present invention that are suitable for pharmaceutical use are those in which the associated solvent is pharmaceutically acceptable. For example, hydrates are an example of pharmaceutically acceptable solvates.

[0075] biological activity The compounds of the present invention have agonist activity at the human Y2R receptor, and therefore can be considered to be Y2R agonists. This can be evaluated, for example, by in vitro or cell binding assays, or by reporter assays. Preferred compounds of the present invention, when tested, for example, according to the assays described in the Examples section below, exhibit activity at the human Y2R receptor that is at least 1 / 10 that of human PYY(3-36), preferably activity that is at least 1 / 5, 1 / 3, or 1 / 2 that of human PYY(3-36). More specific preferred compounds of the present invention exhibit activity at the human Y2R receptor that is at least equivalent to that of human PYY(3-36).

[0076] Methods for assessing activity at the 2YR receptor are well known.

[0077] The compounds, solvates, derivatives, and salts of the present invention meet some, or more preferably all, of the following criteria. 1) sustained biological activity at the human Y2R receptor, resulting in appetite suppression; 2) a low incidence of side effects such as nausea and vomiting, especially at therapeutically effective dose levels; 3) High solubility in aqueous solution at pH 5, which allows effective doses to be administered in low volume injections (thereby reducing injection pain). Solubility can be easily assessed by simple in vitro tests. 4) long-term activity in vivo (as assessed in humans or animal models) that allows injections no more than once per day, preferably no more than twice per week, and more preferably no more than once per week, while maintaining acceptable therapeutic or cosmetic benefit; 5) Low antigenicity in humans, which can be assessed in humans or animal models (particularly mice experimentally reconstituted with a human immune system to mimic the human antibody repertoire), or predicted using predictive software such as those incorporating the "antigenic index" algorithm (Jameson & Wolf (1988) Comput. Appl. Biosci. 4(1):181-6) or the PREDITOP algorithm (Pellequer & Westhof, (1993) J. Mol. Graph. 11(3):204-10), or using the method of Kolaskar & Tongankar (1990) FEBS Leu. 10:276(1-2):172-4, the contents of which are incorporated herein by reference.

[0078] According to certain embodiments of the present invention, particularly those relating to weight loss, obesity, carbohydrate metabolism, and diabetes, the compounds, derivatives, solvates, and salts of the present invention have one, some, or all of the following characteristics: A) Sufficient solubility between pH 4 and pH 5 so that an effective dose can be administered in a volume of less than 1 ml, less than 0.5 ml, or less than 0.3 ml. B) Inhibition of cAMP signaling in human embryonic kidney cells overexpressing the human Y2R receptor. C) Additionally, one, some, or all of the characteristics 1-5 above.

[0079] Pharmacokinetics, duration of action and solubility The compounds of the present invention exhibit effective and extended duration of action in vivo after subcutaneous administration. To achieve this, the compounds must possess both good activity at the biological target and excellent pharmacokinetic properties. Incorporation of His residues into poorly water-soluble peptides typically improves solubility at acidic pHs (e.g., pH 5) due to the presence of the charged His side group, but reduces solubility at physiological pH (pH 7.4). The pI of the histidine side group is approximately 6.0. This property allows for the formulation of His-containing peptides in weakly acidic media. Subcutaneous injection of such formulations reduces solubility, resulting in subcutaneous precipitation of the peptide, which redissolves over time. Zinc-containing formulations of His-containing peptides enhance this effect because, at pH 7.4 but not at pH 5, zinc ions coordinate to the histidine residue, resulting in a further decrease in solubility, which may contribute to increased precipitation at the subcutaneous injection site or improved stability of the precipitate. However, if the peptide does not precipitate rapidly enough after subcutaneous administration, there may still be an initial "spike" or "burst" in the blood concentration levels of the peptide. Such a characteristic is undesirable because it increases the likelihood that the subject will experience side effects, even if temporary, associated with high concentrations of the peptide, such as nausea.

[0080] conditions The present invention also provides a PYY analog according to the present invention, or a pharmaceutical composition comprising a PYY analog, for use as a medicament. The PYY analog and pharmaceutical composition find use in the treatment and / or prevention of conditions such as diabetes and obesity. The PYY analog and pharmaceutical composition comprising a PYY analog also find use in reducing a subject's appetite, reducing a subject's food intake, and / or reducing a subject's calorie intake.

[0081] The present invention also provides the use of a PYY analogue according to the present invention for the manufacture of a medicament for the prevention or treatment of diabetes and / or obesity. The present invention also provides the use of a PYY analogue according to the present invention for the manufacture of a medicament for reducing appetite in a subject, reducing food intake in a subject, and / or reducing caloric intake in a subject.

[0082] The present invention also provides methods for treating or preventing a disease or disorder, or other undesirable physiological condition in a subject, comprising administering to the subject a therapeutically effective amount of a PYY analog according to the present invention, or a pharmaceutical composition comprising a PYY analog.

[0083] The present invention also provides methods for preventing or treating diabetes and / or obesity, reducing appetite, reducing food intake, and / or reducing caloric intake in a subject, comprising administering to the subject a therapeutically effective amount of a PYY analog according to the present invention, or a pharmaceutical composition comprising a PYY analog.

[0084] In one embodiment, the PYY analog or pharmaceutical composition is administered parenterally. In one embodiment, the PYY analog or pharmaceutical composition is administered subcutaneously. In one embodiment, the PYY analog or pharmaceutical composition is administered intravenously, intramuscularly, intranasally, transdermally, or sublingually.

[0085] The subject to whom the PYY analog according to the present invention or a pharmaceutical composition comprising a PYY analog is administered may be overweight, for example, obese. Alternatively, or in addition, the subject may be, for example, a diabetic patient with insulin resistance or impaired glucose tolerance, or both. The subject may have diabetes mellitus, for example, type II diabetes. The subject may be overweight, for example, obese, and may have diabetes mellitus, for example, type II diabetes. Alternatively, the subject may have type I diabetes.

[0086] The PYY analogs of the present invention are believed to protect islet cells, particularly beta cells, allowing them to retain their normal physiological function, such as the ability to secrete insulin in response to appropriate stimuli when confronted with toxins (e.g., streptozotocin), pathogens, or autoimmune responses. The PYY analogs of the present invention are also believed to be effective in restoring or rescuing pancreatic islet function, particularly beta cell function, after a decline in physiological function following exposure to toxins, pathogens, or autoimmune responses. Restoration of function can be at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% of the function exhibited prior to the decline. Accordingly, the present invention also provides PYY analogs of the present invention, or pharmaceutical compositions comprising PYY analogs, for use in preventing the loss of pancreatic islet function (e.g., beta cell function) and / or restoring pancreatic islet function (e.g., beta cell function). The present invention further provides use of a PYY analog of the present invention for the manufacture of a medicament for preventing loss of pancreatic islet function (e.g., beta cell function) and / or restoring pancreatic islet function (e.g., beta cell function). The present invention further provides methods for preventing loss of pancreatic islet function (e.g., beta cell function) and / or restoring pancreatic islet function (e.g., beta cell function) in a subject, comprising administering to the subject an effective amount of a PYY analog of the present invention, or a pharmaceutical composition comprising a PYY analog.

[0087] The islet-protecting properties of the PYY analogs of the present invention make them useful for administration in combination with an additional therapeutic agent that has islet toxicity as a side effect. One example of such a therapeutic agent is streptozotocin. Thus, the present invention also provides a PYY analog of the present invention in combination with an additional therapeutic agent that has islet toxicity as a side effect. The present invention also provides a pharmaceutical composition comprising a PYY analog of the present invention and an additional therapeutic agent that has islet toxicity as a side effect, together with a pharmaceutically acceptable carrier.

[0088] In addition, or alternatively, object may have the disorder that obesity or overweight is a risk factor, or may be at risk of the disorder.Such disorder includes but is not limited to: cardiovascular disease, for example, hypertension, atherosclerosis, congestive heart failure and dyslipidemia; stroke; gallbladder disease; osteoarthritis; sleep apnea; reproductive disorder, for example, polycystic ovarian syndrome; cancer, for example, breast cancer, prostate cancer, colon cancer, endometrial cancer, kidney cancer and esophageal cancer; varicose veins; acanthosis nigricans; eczema; exercise intolerance; insulin resistance; hypertension hypercholesterolemia; cholelithiasis; osteoarthritis; orthopedic trauma; insulin resistance, for example, type II diabetes and syndrome X; and thromboembolic disease (referring to Kopelman, Nature 404:635-43,2000; Rissanen et al, British Med.J.301,835,1990).

[0089] Other disorders related to obesity include depression, anxiety, panic attacks, migraine, premenstrual syndrome, chronic pain conditions, fibromyalgia, insomnia, impulsivity, obsessive-compulsive disorder, and myoclonus.In addition, obesity is a recognized risk factor for the increased incidence of complications of general anesthesia (see, for example, Kopelman, Nature 404:635-43, 2000).In general, obesity shortens lifespan and carries a significant risk of the comorbidities listed above.

[0090] Other diseases or disorders associated with obesity include maternal obesity, which is associated with an increased incidence of congenital anomalies, neural tube defects, carpal tunnel syndrome (CTS), chronic venous insufficiency (CVI), daytime sleepiness, deep vein thrombosis (DVT), end-stage renal disease (ESRD), gout, heat disorders, impaired immune response, respiratory dysfunction, infertility, liver disease, back pain, obstetric and gynecological complications, pancreatitis, and abdominal hernia, acanthosis nigricans, endocrine disorders, chronic hypoxia and hypercapnia, skin effects, These include large anterior abdominal wall masses (e.g., abdominal subcutaneous panniculitis with frequent subcutaneous panniculitis that interferes with walking, causes frequent infections, bad odor, difficulty dressing, and lower back pain), breast hypertrophy, which can cause considerable problems such as elephantiasis, gastroesophageal reflux, heel spurs, leg edema, bra strap pain, skin breakdown, neck pain, and chronic odor and infection in the submammary folds, musculoskeletal disorders, cerebral pseudomasses (or benign intracranial hypertension), and sliding hiatal hernias.

[0091] The present invention also provides a method for improving the lipid profile of a subject, comprising administering to the subject a PYY analog according to the present invention, or a pharmaceutical composition comprising a PYY analog.The present invention also provides a method for alleviating a condition or disorder that can be alleviated by reducing nutrient availability, comprising administering to a subject a PYY analog according to the present invention, or a pharmaceutical composition comprising a PYY analog.

[0092] Appetite can be measured by any means known to those skilled in the art. For example, appetite reduction can be evaluated by psychological assessment. For example, administration of the compound of the present invention causes changes in perceived hunger, satiety, and / or fullness. Hunger can be evaluated by any means known to those skilled in the art. For example, hunger is evaluated using psychological assays, such as but not limited to, by assessing hunger sensation and sensory perception using questionnaires such as visual assessment score (VAS) questionnaires. In a specific, non-limiting example, hunger is evaluated by answering questions about food, drink desire, anticipated food consumption, nausea, and smell or taste perception.

[0093] The PYY analogs of the present invention can be used for weight management and treatment, e.g., reducing or preventing obesity, specifically preventing and reducing weight gain, inducing and promoting weight loss, and reducing obesity as measured by body mass index. The PYY analogs of the present invention can be used to control one or more of appetite, satiety, and hunger, specifically reducing, suppressing, and inhibiting appetite; inducing, increasing, improving, and promoting satiety and feelings of fullness; and reducing, inhibiting, and suppressing hunger and feelings of hunger. The PYY analogs of the present invention can be used to maintain one or more of a desired weight, a desired body mass index, a desired appearance, and good health. Accordingly, the present invention also provides a method for inducing weight loss or preventing weight gain in a subject for cosmetic purposes, comprising administering to the subject an effective amount of a PYY analog of the present invention or a composition comprising a PYY analog.

[0094] The subject may be a subject desiring weight loss, e.g., a male or female subject desiring a change in appearance. The subject may desire a decrease in hunger, e.g., the subject may be an individual involved in long-term work requiring a high level of concentration, such as, for example, an active duty soldier, an air traffic controller, or a truck driver on long routes.

[0095] The present invention may also be used to treat, prevent, ameliorate, or alleviate conditions or disorders caused by, complicated by, or exacerbated by relatively high nutrient availability. The term "condition or disorder that can be alleviated by reducing calorie (or nutrient) availability" is used herein to refer to any condition or disorder in a subject that is caused by, complicated by, or exacerbated by relatively high nutrient availability, or that can be alleviated by reducing nutrient availability, for example, by reducing food intake. Subjects who are insulin resistant, glucose intolerant, or have any type of diabetes mellitus, such as type I, type II, or gestational diabetes, can also benefit from the methods according to the present invention.

[0096] The present invention relates to the treatment of metabolic disorders, such as disorders of energy metabolism, including conditions or disorders associated with increased caloric intake, including, but not limited to, insulin resistance, glucose intolerance, obesity, diabetes, including type II diabetes, eating disorders, insulin resistance syndrome, and Alzheimer's disease.

[0097] According to the present invention, PYY analogs are preferably used to treat humans.However, although the compounds of the present invention are typically used to treat human subjects, they can also be used to treat similar or identical conditions in other vertebrates, such as other primates; livestock, such as pigs, cattle, and poultry; sport animals, such as horses; or companion animals, such as dogs and cats.

[0098] composition While it is possible for the active ingredient to be administered alone, it is preferred that the active ingredient be present in a pharmaceutical formulation or composition. Accordingly, the present invention also provides pharmaceutical compositions comprising a PYY analog according to the present invention, together with a pharmaceutically acceptable carrier and, optionally, other therapeutic ingredients. Pharmaceutical compositions of the present invention may take the form of pharmaceutical formulations as described below.

[0099] Pharmaceutical formulations according to the present invention include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, and intraarticular), inhalation (including fine particle dusts or mists which may be generated by various types of metered dose pressurized aerosols, nebulizers, or inhalers), rectal, and topical (including dermal, transdermal, transmucosal, buccal, intraocular, and ocular) administration, although the most suitable route may depend, for example, on the condition and disorder of the recipient.

[0100] Preparation can be conveniently presented in unit dosage form, and can be prepared by any method known in the field of pharmacy.All methods comprise the step of associating active ingredient with carrier that constitutes one or more auxiliary ingredients.Generally, preparation is prepared by uniformly and intimately associating active ingredient with liquid carrier or finely divided solid carrier or both, and then, if necessary, shaping product into desired preparation.

[0101] The formulations of the present invention suitable for oral administration can be presented as individual units such as capsules, sachets, or tablets, each containing a predetermined amount of active ingredient, as powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.The active ingredient can also be presented as a bolus, electuary, or paste.Various pharmaceutically acceptable carriers and their formulations are described in standard formulation treatises, such as Remington's Pharmaceutical Sciences by EW Martin.See also Wang, YJ, and Hanson, MA, Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S, 1988.

[0102] Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing the active ingredient in a free-flowing form, such as powder or granules, optionally mixed with a binder, glidant, inert diluent, lubricant, surfactant, or dispersant in a suitable machine. Molded tablets may be produced by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine. Tablets may optionally be coated or scored, and may be formulated to provide slow or controlled release of the active ingredient. The compound may be administered in a form suitable for immediate release or extended release, for example. Immediate release or extended release can be achieved by using a suitable pharmaceutical composition containing the compound, or, particularly in the case of extended release, by using a device such as a subcutaneous implant or an osmotic pump. The compound may also be administered as a liposome.

[0103] Preferably, the compositions according to the present invention are suitable for subcutaneous administration, for example, by injection. According to certain embodiments, the compositions may contain metal ions, such as copper, iron, aluminum, zinc, nickel, or cobalt ions. The presence of such ions can limit solubility and thus delay absorption into the circulatory system from the site of subcutaneous administration. In particularly preferred embodiments, the compositions contain zinc ions. The zinc ions can be present at any suitable concentration, for example, in a molar ratio of 10:1 to 1:10, 8:1 to 1:8, 5:1 to 1:5, 4:1 to 1:4, 3:1 to 1:3, 2:1 to 1:2, or 1:1 relative to the peptide molecule. In one embodiment, the pharmaceutical composition has a pH of less than 5, and the pharmaceutical composition contains zinc ions.

[0104] Exemplary compositions for oral administration include suspensions (such as those known in the art) that may contain, for example, microcrystalline cellulose for bulking, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents; and immediate-release tablets that may contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate, and / or lactose, and / or other excipients, binders, fillers, disintegrants, diluents, and lubricants (such as those known in the art). The PYY analogs of the present invention, or variants, derivatives, salts, or solvates thereof, may also be delivered through the oral cavity by sublingual and / or buccal administration. Molded, compressed, or freeze-dried tablets are exemplary forms that can be used. Exemplary compositions include those in which the compound(s) of the present invention are formulated with a fast-dissolving diluent such as mannitol, lactose, sucrose, and / or cyclodextrin. Such formulations may also include high molecular weight excipients such as cellulose (avicel) or polyethylene glycol (PEG). Such formulations may also include excipients to aid adhesion to the mucosa, such as hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), sodium carboxymethyl cellulose (SCMC), maleic anhydride copolymers (e.g., Gantrez), and agents to control release, such as polyacrylic copolymers (Carbopol 934). Lubricants, glidants, flavors, colorants, and stabilizers may also be added for ease of manufacture and use.

[0105] Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions, which may contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions, which may contain suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, such as sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) state, requiring only the addition of a sterile liquid carrier, such as saline or water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets of the type described above. Exemplary compositions for parenteral administration include injectable solutions or suspensions, which may contain, for example, a suitable non-toxic, parenterally acceptable diluent or solvent, such as mannitol, 1,3-butanediol, water, Ringer's solution, isotonic sodium chloride solution, or other suitable dispersing or wetting agent, and suspending agents including synthetic mono- or diglycerides, and fatty acids, including oleic acid or Cremaphor. The aqueous carrier may be, for example, an isotonic buffer solution having a pH of about 3.0 to about 8.0, preferably about 3.5 to about 7.4, e.g., 3.5 to 6.0, e.g., 3.5 to about 5.0. Useful buffers include sodium citrate-citric acid and sodium phosphate-phosphate, and sodium acetate / acetic acid buffers. The composition preferably does not contain oxidizing agents or other compounds known to be harmful to PYY and related molecules. Possible excipients include other proteins, such as human serum albumin or plasma preparations. If desired, the pharmaceutical composition may also contain minor amounts of nontoxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents, e.g., sodium acetate or sorbitan monolaurate.

[0106] In one embodiment, the pharmaceutical composition is present in a syringe or other administration device for subcutaneous administration to a human.

[0107] Exemplary compositions for nasal aerosol or inhalation administration include solutions in saline, which may contain, for example, benzyl alcohol or other suitable preservatives, absorption enhancers to improve bioavailability, and / or other solubilizing or dispersing agents (such as those known in the art). Conveniently, in compositions for nasal aerosol or inhalation administration, the compounds of the present invention are delivered in the form of an aerosol spray from a pressurized pack or nebulizer using a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. In the case of pressurized aerosols, the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges, for example, of gelatin, for use in inhalers or insufflators can be formulated to contain a powder mix of the compound and a suitable powder base, such as lactose or starch. In a specific, non-limiting example, the compounds of the present invention are administered as an aerosol from a metered-dose valve through an aerosol adapter, also known as an actuator. Optionally, stabilizers are also included, and / or porous particles are included for deep lung delivery (see, eg, US Pat. No. 6,447,743).

[0108] Formulations for rectal administration may be prepared as retention enemas or suppositories with conventional carriers such as cocoa butter, synthetic glyceride esters, or polyethylene glycols. Such carriers are typically solid at ordinary temperatures but liquefy and / or melt in the rectal cavity to release the drug.

[0109] Formulations for topical administration in the oral cavity, e.g., buccal or sublingual, include lozenges comprising the active ingredient in a flavored base such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a base such as gelatin and glycerin or sucrose and acacia. An exemplary composition for topical administration comprises a topical carrier such as Plastibase (mineral oil gelled with polyethylene).

[0110] Preferred unit dosage formulations are those containing an effective dose, as herein above recited, of a PYY analog, or an appropriate fraction thereof.

[0111] It will be understood that in addition to the ingredients specifically mentioned above, the formulations of the present invention may include other agents commonly used in the art having regard to the type of formulation in question; for example, formulations suitable for oral administration may include flavoring agents.

[0112] The PYY analogs of the present invention are also suitably administered as sustained-release systems. Suitable examples of sustained-release systems of the present invention include suitable polymeric materials, e.g., semipermeable polymer matrices in the form of shaped articles, e.g., films or microcapsules; suitable hydrophobic materials, e.g., as an emulsion in an acceptable oil; or ion exchange resins; and sparingly soluble derivatives of the compounds of the present invention, e.g., a sparingly soluble salt. The sustained-release systems may be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, or topically, for example, as powders, ointments, gels, drops, or transdermal patches, or as oral or nasal sprays.

[0113] The preparation for administration can be suitably formulated to provide controlled release of the compound of the present invention.For example, pharmaceutical composition can be in the form of particles, which contain one or more of biodegradable polymer, polysaccharide gelling and / or bioadhesive polymer, amphiphilic polymer, agent that can change the surface properties of particles of the compound of formula (I).These compositions exhibit certain biocompatible features that allow controlled release of active substance.See US Patent No. 5,700,486.

[0114] The PYY analogs, derivatives, or salts of the present invention can be delivered by pump (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201, 1987; Buchwald et al., Surgery 88:507, 1980; Saudek et al., N. Engl. J. Med. 321:574, 1989) or by continuous subcutaneous infusion, for example, using a minipump. An intravenous bag solution may also be used. An important factor in selecting the appropriate dose is the results obtained, as measured by reduction in total body weight or the ratio of body fat to lean body mass, or by other criteria for measuring the control or prevention of obesity or obesity-related conditions, as deemed appropriate by the physician. Other controlled-release systems are discussed in the review by Langer (Science 249:1527-1533, 1990). In another aspect of the disclosure, the compounds of the present invention are delivered by an implantable pump, for example, as described in US Pat. No. 6,436,091, US Pat. No. 5,939,380, US Pat. No. 5,993,414.

[0115] Implantable drug infusion device is used to provide patients with constant and long-term dosing or infusion of drugs or any other therapeutic agents.In essence, such devices can be classified as either active or passive.The compound of the present invention can be formulated as depot preparation.Such long-acting depot preparation can be administered by, for example, subcutaneous or intramuscular implantation, or by intramuscular injection.Therefore, for example, compound can be formulated with suitable polymer or hydrophobic material, for example, as emulsion in acceptable oil, or as ion exchange resin, or as sparingly soluble derivative, for example, as sparingly soluble salt.

[0116] The therapeutically effective amount of the PYY analog of the present invention may be administered as a single pulse dose, as a bolus dose, or as pulse doses administered over time. Thus, in a pulse dose, a bolus dose of the PYY analog of the present invention is provided, followed by a period in which the compound of the present invention is not administered to the subject, followed by a second bolus dose. In a specific, non-limiting example, the pulse dose of the compound of the present invention is administered daily, weekly, or monthly.

[0117] The present invention also provides PYY analogs of the present invention together with an additional therapeutic agent for simultaneous, sequential, or separate administration. The present invention also provides pharmaceutical compositions comprising a PYY analog of the present invention and an additional therapeutic agent. Examples of additional therapeutic agents include additional appetite suppressants, agents that reduce food intake, lower plasma glucose, or alter plasma lipids. Specific, non-limiting examples of additional appetite suppressants include amfepramone (diethylpropion), phentermine, mazindol, and phenylpropanolamine, fenfluramine, dexfenfluramine, and fluoxetine. As described above, the PYY analogs of the present invention may be administered simultaneously with the additional appetite suppressant, or may be administered sequentially or separately. In one embodiment, the compounds of the present invention are formulated and administered with the appetite suppressant in a single dose.

[0118] The PYY analogs of the present invention can be administered whenever an effect, e.g., appetite suppression, reduced food intake, or reduced caloric intake, is desired, or shortly before the effect is desired, such as, but not limited to, about 10 minutes, about 15 minutes, about 30 minutes, about 60 minutes, about 90 minutes, or about 120 minutes before the time the effect is desired.

[0119] The therapeutically effective amount of a PYY analog of the present invention will depend on the molecule utilized, the subject being treated, the severity and type of affliction, and the mode and route of administration. For example, a therapeutically effective amount of a PYY analog of the present invention can vary from about 0.01 μg / kilogram (kg) body weight to about 1 g / kg body weight, e.g., from about 0.1 μg to about 20 mg / kg body weight, e.g., from about 1 μg to about 5 mg / kg body weight, or from about 5 μg to about 1 mg / kg body weight.

[0120] In one embodiment of the present invention, the PYY analog of the present invention may be administered to a subject at a dose of 5 to 1000 nmol / kg body weight, e.g., 10 to 750 nmol / kg body weight, e.g., 20 to 500 nmol / kg body weight, specifically 30 to 240 nmol / kg body weight. For a 75 kg subject, such a dose corresponds to a dose of 375 nmol to 75 μmol, e.g., 750 nmol to 56.25 μmol, e.g., 1.5 to 37.5 μmol, specifically 2.25 to 18 μmol.

[0121] In alternative embodiments, the PYY analogs of the present invention may be administered to a subject at 0.5 to 135 picomoles (pmol) / kg body weight, e.g., 5 to 100 picomoles (pmol) / kg body weight, e.g., 10 to 90 picomoles (pmol) / kg body weight, e.g., about 72 pmol / kg body weight. In a specific, non-limiting example, the PYY analogs of the present invention are administered at a dose of about 1 nmol or more, 2 nmol or more, or 5 nmol or more. In this example, the dose of the PYY analogs of the present invention is generally 100 nmol or less, e.g., doses of 90 nmol or less, 80 nmol or less, 70 nmol or less, 60 nmol or less, 50 nmol or less, 40 nmol or less, 30 nmol or less, 20 nmol or less, or 10 nmol. For example, a dosage range may include any combination of any of the specified lower dose limits with any of the specified upper dose limits. Thus, non-limiting examples of dosage ranges for the compounds of the present invention are within the ranges of 1 to 100 nmol, 2 to 90 nmol, and 5 to 80 nmol.

[0122] In one specific, non-limiting example, about 1 to about 50 nmol of a PYY analog of the present invention is administered, e.g., about 2 to about 20 nmol, e.g., about 10 nmol, administered as a subcutaneous injection. The exact dose can be readily determined by one of skill in the art based on the potency of the particular PYY analog utilized, the route of delivery of the PYY analog, and the age, weight, sex, and physiological condition of the subject.

[0123] Suitable doses of the PYY analogs of the present invention also include those that result in a reduction in caloric intake, food intake, or appetite caused by normal postprandial PYY levels. Exemplary doses include, but are not limited to, doses that produce an effect demonstrated when serum levels of PYY are about 40 pM to about 60 pM, or about 40 pM to about 45 pM, or about 43 pM.

[0124] The doses discussed above can be provided, for example, once, twice, three times, or four times a day. Alternatively, they can be provided once every 2, 3, or 4 days. For sustained-release formulations containing zinc, it may be possible to provide a dose once every 3, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days. According to certain embodiments, they can be administered once just before each meal is consumed.

[0125] Specific sequences of the present invention According to certain specific embodiments of the present invention, the PYY analog has a given amino acid sequence of one of the specific sequences shown in FIG. [Example]

[0126] The invention is illustrated by the following non-limiting examples.

[0127] material and method Peptide synthesis Peptides were synthesized using standard fluorenylmethoxycarbonyl (Fmoc) solid-phase peptide synthesis (SPPS) methods. Peptide synthesis was performed on a tricyclic amide linker resin. Amino acids were attached using the Fmoc strategy. Each amino acid was added sequentially from the C-terminus to the N-terminus. Peptide coupling was mediated by reagents such as TBTU. Peptide cleavage from the resin was achieved using trifluoroacetic acid in the presence of a scavenger.

[0128] Peptides were purified by reverse-phase HPLC. Quality control was performed on all purified peptides, and peptides were shown to be >90% pure in most cases by HPLC in two buffer systems. MALDI-MS showed the expected molecular ion.

[0129] Exemplary Synthesis Exemplary compound Y1592 was prepared as follows using standard Fmoc chemistry.

[0130] 1. Resin Preparation: To 2Cl-Trt resin (0.30 mmol, 1.00 eq) was added FMOC-TYR(TBU)-OH (137.86 mg, 300.00 μmol, 1.00 eq) and DIEA (232.63 mg, 1.80 mmol, 313.52 μL, 6.00 eq) in DCM (10.0 mL). The mixture was stirred under N2 for 2 h at 20 °C, then MeOH (0.3 mL) was added, and the mixture was stirred under N2 for an additional 30 min. The resin was washed with DMF (3 × 15.0 mL), then 20% piperidine in DMF (5.00 mL) was added, and the mixture was stirred under N2 for 30 min at 20 °C. The mixture was filtered to obtain the resin. The resin was washed with DMF (5 × 15.0 mL), and the mixture was filtered to obtain the resin.

[0131] 2. Coupling: A solution of FMOC-ARG(PBF)-OH (583.89 mg, 900.00 μmol, 3.00 eq), DIEA (232.63 mg, 1.80 mmol, 313.52 μL, 6.00 eq) and HBTU (324.25 mg, 855.00 μmol, 2.85 eq) in DMF (5.00 mL) was added to the resin and stirred with N for 30 min at 20 °C. The resin was then washed with DMF (3 × 15.0 mL).

[0132] 3. Deprotection: 20% piperidine in DMF (5.00 mL) was added to the resin, and the mixture was stirred with N2 for 30 minutes at 20° C. The resin was washed with DMF (5×15.0 mL) and filtered to obtain the resin.

[0133] 4. Steps 2 and 3 were repeated using the reagents in Table 3 until the last amino acid was added (reaction iteration number 1 in Table 3 is the first Arg residue added, as described in step 2 above). [Table 4]

[0134] 5. After coupling of tert-butoxycarbonyl tert-butyl carbonate in iteration 37, 3% H2N·NH2 / DMF was added and reacted for 30 min to remove DDE, then repeated. The mixture was then drained and washed with DMF (5 × 20.0 mL).

[0135] 6. Steps 2 and 3 of the reaction were then carried out using 16-(tert-butoxy)-16-oxohexadecanoic acid (3.00 eq) in HBTU (2.85 eq) and DIEA (6.00 eq).

[0136] Peptide cleavage and purification The resin was washed with MeOH (2 × 30.0 mL) and dried under vacuum to give 2.20 g of peptide resin. Then, 25.0 mL of cleavage buffer (92.5% TFA / 2.5% Mpr / 2.5% TIS / 2.5% HO) was added to the flask containing the side-chain protected peptide resin at 20 °C, and the mixture was stirred for 2 h. The peptide was precipitated with cold tert-butyl methyl ether (300 mL) and centrifuged (5000 rpm for 3 min). The peptide precipitate was washed two more times with tert-butyl methyl ether (150 mL). The crude peptide was dried under vacuum for 2 h and confirmed by LCMS (EW18009-1-P1A1).

[0137] The residue was purified by preparative HPLC (TFA, conditions: 30° C., A: 0.075% TFA / H 2 O, B: CH 3 CN) to give the compound as a white solid, which was confirmed by LCMS (EW18009-1-P1A) and HPLC (EW18009-1-P1B).

[0138] Figure 1 discloses a number of specific sequences that are within the scope of the present invention in all its aspects. Each of these sequences is a specific embodiment of the present invention. Also disclosed in the first line is the sequence of naturally occurring human PYY for reference.

[0139] Human Y2 receptor, in vitro receptor potency study DiscoverX® hY2 CHO-K1 cells (10,000 cells per well in a 96-well plate) were resuspended for 30 minutes in medium containing 0.1% (vol / vol) BSA and 0.01 mM forskolin, as well as a range of test peptide concentrations. The reaction was stopped by lysing the cells, and cAMP was quantified after 60 minutes using the Cisbio cAMP dynamic 2 kit. Y2R agonists inhibit forskolin-stimulated cAMP production. IC 50 Values ​​are for the control peptide of the present invention (PYY 3-36 ) and calculated for the test peptide. Test peptide: PYY 3-36 The ratio is calculated as 1 = PYY 3-36= 10-fold higher potency, 0.1 = 10-fold lower potency, and 10 = 10-fold lower potency. The mean (average) ratio is calculated from independent trials.

[0140] Test compound: PYY 3-36 The inhibition of cAMP production, expressed as a ratio of 1:1, is shown in FIG. 2 in the column headed "Human cAMP Inhibition."

[0141] solubility studies The solubility of the compounds of the present invention was evaluated by preparing a solution of the compound at 50 mg / mL by dissolving 2 mg of material in 0.04 mL of water for injection. The pH of the solution was adjusted to pH 4. Solubility is assessed by visual inspection in the following cases: 1 = Identical to the diluent, easily soluble, clear solution visibility 2 = Soluble with few (<3) visible particles 3 = Soluble with a medium number (3-10) of visible particles 4 = Many insoluble particles in the suspension, opaque 5 = insoluble, precipitate present

[0142] The results of this study are shown in Figure 2 in the column headed "Solubility at 50 mg / ml pH 4."

[0143] In vivo efficacy study, single dose dietary study in male Wistar rats animal Ad libitum-fed male Wistar rats (Charles River Ltd, Margate, UK) were used in animal experiments.

[0144] Dietary studies in rats Rats were housed individually in IVC cages. Animals were randomized into treatment groups using weight stratification. All peptide solutions were freshly prepared immediately before administration. The vehicle used for all studies was 5% v / v water and 95% NaCl (0.9% w / v). Compounds of the invention (at either 100, 200, or 400 nmol / kg body weight) were resuspended in water for injection. Peptides and vehicle were administered by subcutaneous injection during the early light phase (0900 h to 1000 h), and animals were provided with a known amount of food.

[0145] Animals had free access to food and water throughout the study. Animal weights and remaining food were weighed throughout the study, typically at 24, 48, 72, 96, and 168 hours post-dose.

[0146] result Results were calculated by comparing the change in food intake and weight of individual rats to the mean change in saline control animals and are expressed as treatment group means (mean). For example, a food intake value of "-16" indicates an average reduction of 16 g of food intake compared to the mean food intake of control animals in the study over the same time interval.

[0147] Figure 2 shows the results of a rat feeding study in which male Wistar rats were administered an exemplary compound of the invention. The values ​​shown are the difference in food intake and weight loss between rats receiving control saline or peptide in water for injection over 24 hours, 48 ​​hours, 72 hours, 96 hours, and 7 days. The longevity values ​​represent a score indicating the longevity of the exemplary peptide's effect on food intake and weight loss, with larger values ​​indicating a longer-lasting effect.

Claims

1. A compound of formula I, C-NH ２ Formula I, wherein C is the following peptide sequence: Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Pro8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19- Tyr20-Tyr21-Xaa22-Xaa23-Xaa24-Xaa25-Xaa26-Xaa27-Leu28-Asn29-Xaa30-Xaa31-Thr32-Arg33-Gln34-Arg35-Tyr36 Xaa2 is Pro, Xaa3 is He, Xaa4 is Lys; Xaa5 is Pro, Xaa6 is Glu, Xaa7 is Ala, Xaa9 is Gly; Xaa10 is Lys substituted at its ε-amino group; Xaa11 is Asp, Gly, or Glu; Xaa12 is Ala, Xaa13 is Ser, Xaa14 is Pro, Xaa15 is Glu, Xaa16 is Glu, Xaa17 is Leu or He; Xaa18 is Leu or Val, Xaa19 is Arg, Lys, or His; Xaa22 is Ala or He, Xaa23 is Ala or Glu, Xaa24 is Leu; Xaa25 is Arg, Xaa26 is His, Xaa27 is Phe; Xaa30 is Arg, Lys, or His; Xaa31 is Val or Leu; A compound having a single substitution attached to the ε-amino group of a Lys residue at position Xaa10, wherein the substituent is selected from: (a) a group of the following formula: 【Chemistry 1】 (Wherein R is C ８ -C ２８ is an alkylene or alkenylene chain, R １ is CO ２ H) (b) Z-Cys-S-, wherein Z is a group of the formula: 【Chemistry 2】 (Wherein R is C ８ -C ２８ is an alkylene or alkenylene chain, R １ is CO ２ H) (c) Z-Cys-S-, wherein Z is a group of the formula: 【Transformation 3】 (Wherein R is C ８ -C ２８ is an alkylene or alkenylene chain, R １ is CO ２ H), or (d) X-Q- (Wherein Q is the following: Xaa65-Xaa64-Xaa63-Xaa62-Xaa61, [In the formula, Xaa61 is Gly, Xaa62 is Ser, Xaa63 is Gly, Xaa64 is Ser, Xaa65 is Gly. Xaa64-Xaa63-Xaa62-Xaa61, [In the formula, Xaa64 is Gly, Ser, or Thr; Xaa63 is Ser, Thr, or Gly; Xaa62 is Gly or Ser, Xaa61 is Ser, Thr, Gly, or Asp. Xaa63-Xaa62-Xaa61, [In the formula, Xaa63 is Gly, Pro, Glu, Ser, or Thr; Xaa62 is Ser, Thr, or Gly; Xaa61 is Gly or Thr. Xaa62-Xaa61, and [In the formula, Xaa62 is Ser, Gly, Tyr, Thr, or Asn; Xaa61 is Gly, Thr, His, or Ser. Xaa61, [In the formula, Xaa61 is Gly, Glu, Lys, Asn, or Gln. a peptide sequence or a single amino acid residue selected from X is a group of the formula: 【Chemistry 4】 In the formula, R is C ８ -C ２８ is an alkylene or alkenylene chain, R １ is CO ２ H), Or its salt.

2. 2. The compound of claim 1 , A compound having a single substitution attached to the ε-amino group of a Lys residue at position Xaa10, said substitution being selected from: a, a group of the following formula: 【Transformation 5】 (Wherein R is C ８ -C ２８ is an alkylene or alkenylene chain, R １ is CO ２ H), or d, X-Q- (Wherein Q is the following: Xaa65-Xaa64-Xaa63-Xaa62-Xaa61, [In the formula, Xaa61 is Gly, Xaa62 is Ser, Xaa63 is Gly, Xaa64 is Ser, Xaa65 is Gly. Xaa63-Xaa62-Xaa61, [In the formula, Xaa63 is Gly, Pro, Glu, Ser, or Thr; Xaa62 is Ser, Thr, or Gly; Xaa61 is Gly or Thr. Xaa62-Xaa61, and [In the formula, Xaa62 is Ser, Gly, Tyr, Thr, or Asn; Xaa61 is Gly, Thr, His, or Ser. Xaa61, [In the formula, Xaa61 is Gly, Glu, Lys, Asn, or Gln. a peptide sequence or a single amino acid residue selected from X is a group of the formula: 【Transformation 6】 In the formula, R is C ８ -C ２８ is an alkylene or alkenylene chain, R １ is CO ２ H), Or its salt.

3. 3. The compound or salt according to claim 1, wherein Q is Gly65-Ser64-Gly63-Ser62-Gly61.

4. Q is Xaa64-Xaa63-Xaa62-Xaa61; 2. The compound or salt according to claim 1, wherein Xaa64 is Gly, Ser, or Thr, Xaa63 is Ser, Thr, or Gly, Xaa62 is Gly or Ser, and Xaa61 is Ser, Thr, Gly, or Asp.

5. 2. The compound or salt according to claim 1, wherein Q is Xaa63-Xaa62-Xaa61, Xaa63 is Gly, Pro, Glu, Ser, or Thr, Xaa62 is Ser, Thr, or Gly, and Xaa61 is Gly or Thr.

6. 2. The compound or salt according to claim 1, wherein Q is Xaa62-Xaa61, Xaa62 is Ser, Gly, Tyr, Thr, or Asn, and Xaa61 is Gly, Thr, His, or Ser.

7. 2. The compound or salt of claim 1, wherein Q is Xaa61, and Xaa61 is Gly, Glu, Lys, Asn, or Gln.

8. The compound or salt according to claim 2, wherein Q is Gly63-Ser62-Gly61.

9. The compound or salt according to claim 2, wherein Q is Glu63-Gly62-Thr61.

10. The compound or salt according to claim 2, wherein Q is Asn62-His61.

11. 3. The compound or salt according to claim 2, wherein Q is Glu61.

12. 3. The compound or salt according to claim 2, wherein Q is Gly61.

13. R is C １８ , C １６ , or C １４ Alkylene chain, or C １８ , C １６ , or C １４ The compound or salt according to any one of claims 1 to 12, which is an alkenylene chain.

14. Additional features include: A, Xaa11 is Gly or Glu, B. Xaa19 is His; 14. The compound or salt of any one of claims 1, 2, 3, 4, 5, 6, or 13, having one or more of:

15. 15. The compound or salt of claim 14 having Feature B.

16. The table below: Table 1 Table 2 wherein the Lys residue at position Xaa10 is selected from the group consisting of the amino acid sequence of Y1596, Y1622, Y1642, Y1739, Y1740, Y1741, Y1783, Y1786, Y1788, Y1797, Y1798, Y1799, Y1800, Y1801, Y1802, Y1803, Y1804, Y1805, Y1821, Y1822, Y1823, or Y1824 shown in Table 3 Table 4 Table 5 Table 6 2. The compound of claim 1, or a salt thereof, as defined in

17. A composition comprising a compound, or salt, according to any one of claims 1 to 16 in combination with a further therapeutic agent for simultaneous, sequential or separate administration.

18. A composition comprising a compound or salt according to any one of claims 1 to 16, together with a pharmaceutically acceptable carrier, and optionally a further therapeutic agent (e.g., an appetite suppressant that is a GLP-1 derivative).

19. 20. The composition of claim 18, present in a syringe or other administration device for subcutaneous administration to a human.

20. A compound or salt according to any one of claims 1 to 16, or a composition according to claim 18 or 19, for use as a medicament.

21. A medicament for treating or preventing a disease or disorder or other undesirable physiological condition in a subject, the medicament comprising a therapeutically effective amount of a compound or salt according to any one of claims 1 to 13, or a composition according to any one of claims 17 to 20.

22. 21. A compound or salt according to any one of claims 1 to 13, or a composition according to any one of claims 17 to 20, for use in the prevention or treatment of diabetes, obesity, heart disease, stroke, and non-alcoholic fatty liver disease, for improving insulin release in a subject, for improving carbohydrate metabolism in a subject, for improving the lipid profile of a subject, for reducing appetite, for reducing food intake, for reducing calorie intake, for improving carbohydrate tolerance in a subject, and / or for use as a cytoprotective agent.

23. 23. The compound, salt, or composition for use as a cytoprotective agent of claim 22, wherein the compound, salt, or composition is for use in preventing or treating neurodegeneration, providing neuroprotection, and / or providing cardioprotection.

24. 24. The compound, salt, or composition for use as a cytoprotective agent of claim 23, wherein the compound, salt, or composition is for providing cardioprotection in a subject following a myocardial infarction.

25. 24. The compound, salt, or composition for use as a cytoprotective agent of claim 23, wherein the compound, salt, or composition is for providing neuroprotection in a subject diagnosed with or at risk of having a chronic neurodegenerative disease.

26. The chronic neurodegenerative disease is Alzheimer's disease, Parkinson's disease, Gehrig's disease (amyotrophic lateral sclerosis), Huntington's disease, multiple sclerosis, other demyelination-related disorders, senile dementia, subcortical dementia, arteriosclerotic dementia, AIDS-related dementia, other dementias, cerebral vasculitis, epilepsy, Tourette's syndrome, Guillain-Barre syndrome, Wilson's disease, Pick's disease, neuroinflammatory disorders, encephalitis, encephalomyelitis, meningitis, other central nervous system infections, prion diseases, cerebellar ataxia, cerebellar degeneration, spinocerebellar degeneration syndrome, Friedreich's ataxia, ataxia-telangiectasia 26. The compound, salt, or composition for use according to claim 25, wherein the compound, salt, or composition is selected from the group consisting of: spinal dysmyotrophy, progressive supranuclear palsy, dystonia, muscle spasms, tremor, retinitis pigmentosa, striatonigral degeneration, mitochondrial encephalomyopathy, and neuronal ceroid lipofuscinosis.

27. 20. A medicament for treating or preventing diabetes, obesity, heart disease, stroke, or non-alcoholic fatty liver disease in a subject, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, reducing calorie intake, and / or providing cytoprotection in a subject, said medicament comprising a therapeutically effective amount of a compound or salt of any one of claims 1 to 16, or a composition of any one of claims 17 to 19.

28. Use of a compound or salt according to any one of claims 1 to 16, or a composition according to claim 17, for the manufacture of a medicament for the prevention or treatment of diabetes, obesity, heart disease, stroke, and non-alcoholic fatty liver disease, for the manufacture of a medicament for improving insulin release in a subject, for the manufacture of a medicament for improving carbohydrate metabolism in a subject, for the manufacture of a medicament for improving the lipid profile of a subject, for the manufacture of a medicament for improving carbohydrate tolerance in a subject, for the manufacture of a medicament for reducing appetite, for the manufacture of a medicament for reducing food intake, for the manufacture of a medicament for reducing calorie intake, and / or for use as a cytoprotective agent.

29. A medicament for causing weight loss or preventing weight gain in a subject for cosmetic purposes, the medicament comprising an effective amount of a compound or salt according to any one of claims 1 to 16, or a composition according to any one of claims 17 to 19.

Images